Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

Inclusion Criteria:

• Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or diagnosis of recurrent chronic lymphocytic leukemia
• Patient has received at least one prior treatment with standard chemotherapy and at least one prior treatment with rituximab (negative HAHA test required if received prior humanized antibody treatment)
• Patient has not received anti-cancer therapy within 28 days of treatment unless disease progression has been demonstrated and toxicities from prior therapy have resolved
• Available tumor tissue (lymph node/mass, blood or bone marrow) for correlative analyses (paraffin or frozen, recent or archived)
• Measurable disease as defined by a tumor mass > 1.5 cm in one dimension or WBC > 5,000 (CLL patients)
• Age > 18 years
• Patient has KPS > 50%
• Absolute granulocyte count > 1000 cells/mm3
• Platelet count > 50,000 cells/mm3
• Creatinine < 2.0 x ULN
• Total bilirubin < 2.0 x ULN
• Patient agrees to use birth control if of reproductive potential
• Patient has signed IRB-approved informed consent

Exclusion Criteria:

• Known central nervous system (CNS) involvement by lymphoma
• Known HIV disease
• Patient is pregnant or nursing
• Patient is receiving other investigational drugs
• Known serum human anti-human antibodies (HAHA)
• Estimated life expectancy of < 3 months